Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
Highlighted with 31 tables and 51 figures, this 110-page report “Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Active Pharmaceutical Ingredients (API)
o Branded Drugs
o Generic Drugs
• Finished Dosage Formulations (FDF)
o Oral Solid Drugs
o Injectable Drugs
o Semi-solid or Liquid Drugs
o Other FDFs
Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Preclinical Use
• Clinical Use
o Phase I
o Phase II
o Phase III
o Phase IV
• Commercial Use
By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical Firms
• Biotechnology Firms
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Boehringer Ingelheim
Cambrex Corporation
Catalent
Cipla
Covance Inc.
Lonza Group Ltd.
Medley Pharmaceuticals
NatcoPharma
Patheon (Thermo Fisher Scientific, Inc.)
Piramal Pharma Solutions
RedHillBiopharma
Siegfried Holding AG
STA Pharmaceutical
Sun Pharmaceutical
Teva
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35
3 Segmentation of Asia Pacific Market by Product Type 39
3.1 Market Overview by Product Type 39
3.2 Active Pharmaceutical Ingredients (API) 41
3.2.1 Branded Drugs 42
3.2.2 Generic Drugs 43
3.3 Finished Dosage Formulations (FDF) 44
3.3.1 Oral Solid Drugs 46
3.3.2 Injectable Drugs 47
3.3.3 Semi-solid or Liquid Drugs 48
3.3.4 Other FDFs 49
4 Segmentation of Asia Pacific Market by Service Type 50
4.1 Market Overview by Service Type 50
4.2 Preclinical Use 52
4.3 Clinical Use 53
4.3.1 Phase I 55
4.3.2 Phase II 56
4.3.3 Phase III 57
4.3.4 Phase IV 58
4.4 Commercial Use 59
5 Segmentation of Asia Pacific Market by Customer Type 60
5.1 Market Overview by Customer Type 60
5.2 Pharmaceutical Firms 62
5.3 Biotechnology Firms 63
6 Segmentation of Asia Pacific Market by Therapeutic Area 64
6.1 Market Overview by Therapeutic Area 64
6.2 Infectious Diseases 66
6.3 Oncology 67
6.4 Ophthalmology 68
6.5 Cardiovascular Disorders 69
6.6 Central Nervous System 70
6.7 Respiratory Disorders 71
6.8 Metabolic Diseases 72
6.9 Other Therapeutic Areas 73
7 Asia-Pacific Market 2021-2031 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 Japan 77
7.3 China 80
7.4 Australia 82
7.5 India 84
7.6 South Korea 86
7.7 Rest of APAC Region 88
8 Competitive Landscape 90
8.1 Overview of Key Vendors 90
8.2 New Product Launch, Partnership, Investment, and M&A 93
8.3 Company Profiles 94
Boehringer Ingelheim 94
Cambrex Corporation 96
Catalent 97
Cipla 98
Covance Inc. 99
Lonza Group Ltd. 100
Medley Pharmaceuticals 101
NatcoPharma 102
Patheon (Thermo Fisher Scientific, Inc.) 103
Piramal Pharma Solutions 104
RedHillBiopharma 105
Siegfried Holding AG 106
STA Pharmaceutical 107
Sun Pharmaceutical 108
Teva 109
RELATED REPORTS 110
List of Tables:
Table 1. Snapshot of Asia Pacific Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. Worldwide Total Number of Registered Clinical Trials 27
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule CDMO Market 31
Table 5. Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 39
Table 6. Asia Pacific Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 41
Table 7. Asia Pacific Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 45
Table 8. Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 50
Table 9. Asia Pacific Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 60
Table 11. Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 64
Table 12. APAC Small Molecule CDMO Market by Country, 2021-2031, $ mn 75
Table 13. Japan Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 79
Table 14. Japan Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 79
Table 15. Japan Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 79
Table 16. China Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 81
Table 17. China Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 81
Table 18. China Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 81
Table 19. Australia Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 83
Table 20. Australia Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 83
Table 21. Australia Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 83
Table 22. India Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 85
Table 23. India Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 85
Table 24. India Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 85
Table 25. South Korea Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 87
Table 26. South Korea Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 87
Table 27. South Korea Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 87
Table 28. Small Molecule CDMO Market in Rest of APAC by Country/Region, 2021-2031, $ mn 89
Table 29. Boehringer Ingelheim: Company Snapshot 94
Table 30. Boehringer Ingelheim: Business Segmentation 95
Table 31. Boehringer Ingelheim: Product Portfolio 95
